<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375606</url>
  </required_header>
  <id_info>
    <org_study_id>CSL730_1001</org_study_id>
    <secondary_id>2017‐003478‐15</secondary_id>
    <nct_id>NCT03375606</nct_id>
  </id_info>
  <brief_title>Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous CSL730 in Healthy Caucasian and Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of ascending doses of CSL730 after a single intravenous
      (IV) infusion in healthy Caucasian and Japanese subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">September 22, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with adverse events overall, and by causality and severity</measure>
    <time_frame>Up to 8 weeks after infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of CSL730 in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the last collection time (AUC0-last) of CSL730 in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 extrapolated to time infinity (AUC0-inf) of CSL730 in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of CSL730 in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T1/2) of CSL730 in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total systemic clearance (CL) of CSL730 in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during the elimination phase (Vz) of CSL730 in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with anti-CSL730 antibodies in serum</measure>
    <time_frame>Before study drug infusion and up to 56 days after the start of the infusion.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CSL730</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL730</intervention_name>
    <description>Solution for IV infusion</description>
    <arm_group_label>CSL730</arm_group_label>
    <other_name>Recombinant trivalent human IgG1 Fc multimer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution for IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females (postmenopausal or surgically sterile only) aged ≥ 20 to ≤ 55
             years and of Caucasian or Japanese descent

        Exclusion Criteria:

          -  Evidence of a clinically significant medical condition, disorder, or disease as judged
             by Investigator and / or study Medical Monitor.

          -  History of asthma (with the exception of childhood asthma that has resolved), chronic
             obstructive pulmonary disease, or recurrent or current respiratory infections;
             splenectomy; or recurrent or current gastrointestinal infections.

          -  Evidence of active or latent tuberculosis.

          -  Known or suspected hypersensitivity to the IP, to any excipients of the IP, humanized
             monoclonal antibodies, or Fc fusion protein therapeutics.

          -  History, or current diagnosis, of substance use disorder.

          -  Any abnormal clinical laboratory values deemed clinically significant by the
             Investigator and / or study Medical Monitor.

          -  Positive serology test result for human immunodeficiency virus antibody, hepatitis
             virus B surface antigen or hepatitis virus C antibody at Screening.

          -  Donation or loss of ≥ 480 mL of whole blood within 2 months or donation of plasma
             within 14 days before Day -1.

          -  Plans to participate in another investigational drug study while enrolled in this
             study, or has participated in any other investigational drug study in which they were
             known to have been administered a monoclonal antibody or biological IP within 4
             months, any other investigational drug study within 60 days or &gt; 3 investigational
             drug studies within 12 months before IP administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>+1 610 878 4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

